Frequency and effects of seasonal flu vaccines on exacerbations of chronic obstructive pulmonary disease in Serbia
Abstract
Background/Aim. The influenza virus is often the cause of exacerbations among chronic obstructive pulmonary disease (COPD) patients, especially during the winter season. However, vaccination rates are still below recommended even in developed countries. The aim of the study was to determine the rates and examine the effectiveness of immunization against seasonal influenza in preventing exacerbations among COPD patients in Serbia. Methods. The prospective cohort study of stable COPD outpatients was conducted over three years (between October 1, 2014, and September 30, 2017) at the Polyclinic Department of Institute for Pulmonary Diseases of Vojvodina, Sremska Kamenica, Serbia. The rates and effects of seasonal flu vaccination on COPD exacerbation rates were evaluated using univariate and multivariate logistic regression analysis, taking into account comorbidity, age, and body mass index (BMI). Results. The study included 840 patients. The flu vaccination rate was 37.1%. Exacerbations occurred more frequently in unvaccinated patients [176 (31.9%) vs. 375 (68.1%), p = 0.043]. In elderly vaccinated patients (≥ 65 years) there were fewer exacerbations compared to unvaccinated patients [89 (56.0%) vs. 188 (69.4%), p = 0.005]. Lower frequency of exacerbations was also observed in vaccinated patients with comorbidities [165 (61.1%) vs. 327 (69.4%), p = 0.021] and low BMI [27 (64.3%) vs. 78 (83.9%), p = 0.011]. Multivariate logistic regression analysis identified BMI < 21 kg/m2 [relative risk (RR): 0.490; 95% confidence interval (CI): 0.318–0.758; p = 0.001] and heart failure (RR: 2.734; 95% CI: 1.121–6.669; p = 0.027) as independent predictors of COPD exacerbations. Conclusion. Immunization for seasonal influenza in Serbia is below recommended rates. Flu vaccination was associated with a significant reduction in COPD exacerbation rates, particularly in elderly patients and patients with heart failure and low BMI.
References
Global Initiative for Chronic Obstructive Lung Disease-GOLD. Global Strategy for the Diagnosis, Management and Prevention of COPD. Bethesda: Global Initiative for Chronic Obstructive Lung Disease, Inc.; 2017 [cited 2017 Mar 25]. Available from: http:// goldcopd.org/gold-2017-global-strategy-diagnosis-management-prevention-copd/
GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a sys-tematic analysis for the global burden of disease study 2013. Lancet 2015; 385(9963): 117–71.
Ehteshami-Afshar S, FitzGerald JM, Doyle-Waters MM, Sa-datsafavi M. The global economic burden of asthma and chronic obstructive pulmonary disease. Int J Tuberc Lung Dis 2016; 20(1): 11‒23.
Zhang W, Webster R. Can we beat influenza? Science 2017; 357(6347): 111.
Miravitlles M, Anzueto A. Role of infection in exacerbations of chronic obstructive pulmonary disease. Curr Opin Pulm Med 2015; 21(3): 278–83.
Mohan A, Chandra S, Agarwal D, Guleria R, Broor S, Gaur B, et al. Prevalence of čno viral infection detected by PCR and RT-PCR in patients with acute exacerbation of COPD: a system-atic review. Respirology 2010; 15(3): 536–42.
World Health Organisation. A Manual for Estimating Disease Burden Associated With Seasonal Influenza. Geneva: World Health Organization; 2015. p. 8‒17.
European Centre for Disease Prevention and Control. Implementa-tion of the Council Recommendation on seasonal influenza vaccination (2009/1019/EU). Stockholm: Technical Report; 2014; p. 3‒18.
Covicković Sternic N. National quide to good clinical practice for diagnosis and treatment of COPB. Republic expert commision for designing and implementing good clinical practice quides. Belgrade: the Ministry of health of the Republic of Serbia; 2013. ISBN: 978-86-83607-85-3 (Serbian)
Burge S, Wedzicha JA. COPD exacerbations: definitions and classifications. Eur Respir J Suppl 2003; 41: 46s‒53s.
Fleming DM, Elliot AJ. The impact of influenza on the health and health care utilisation of elderly people. Vaccine 2005; 23(Suppl 1): S1‒9.
Anzueto A. Impact of exacerbations on COPD. Eur Respir Rev 2010; 19(116): 113–8.
Sethi S. Infection as a comorbidity of COPD. Eur Respir J 2010; 35(6): 1209‒15.
Sanei F, Wilkinson T. Influenza vaccination for patients with chronic obstructive pulmonary disease: understanding immu-nogenicity, efficacy and effectiveness. Ther Adv Respir Dis 2016; 10(4): 349‒67.
European Centre for Disease Prevention and Control. Seasonal in-fluenza vaccination in Europe. Vaccination recommendations and coverage rates in the EU Member States for eight influen-za seasons 2007–2008 to 2014–2015. Stockholm: Technical Report; 2017. p. 5‒16.
Grohskopf LA, Sokolow LZ, Broder KR, Walter EB, Bresee JS, Fry AM, et al. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2017-18 Influenza Season. MMWR Recomm Rep 2017; 66(2): 1‒20.
Evensen A. Management of COPD Exacerbations. Am Fam Physician 2010; 81(5): 607‒13.
Aka Aktürk Ü, Görek Dilektaşlı A, Şengül A, Musaffa Salepçi B, Oktay N, Düger M, et al. Influenza and Pneumonia Vaccina-tion Rates and Factors Affecting Vaccination among Patients with Chronic Obstructive Pulmonary Disease. Balkan Med J 2017; 34(3): 206‒11.
Poole P, Chacko EE, Wood-Baker R, Cates CJ. Influenza vaccine for patients with chronic obstructive pulmonary disease Cochrane Database Syst Rev 2006; (1): CD002733.
Nichol KL, Baken L, Nelson A. Relation between influenza vaccination and outpatient visits, hospitalisation and mortality in elderly persons with chronic lung disease. Ann Intern Med 1999; 130(5): 397‒403.
Montserrat-Capdevila J, Godoy P, Marsal JR, Cruz I, Solanes M. Effectiveness of influenza vaccination in preventing hospital admission due to exacerbations of chronic obstructive pulmo-nary disease. Enferm Infecc Microbiol Clin 2014; 32(2): 70–5. (Spanish)
Seo YB, Choi WS, Baek JH, Lee J, Song JY, Lee JS, et al. Effec-tiveness of the influenza vaccine at preventing hospitalization due to acute exacerbation of cardiopulmonary disease in Ko-rea from 2011 to 2012, Hum Vaccin Immunother 2014; 10(2): 423–7.
Gajanan G, Hattiholi J, Chaudhury A. Risk factors for frequent hospital readmissions for acute exacerbations of COPD. Clin Med Res 2013; 2(6): 167‒73.
Søgaard M, Madsen M, Løkke A, Hilberg O, Sørensen HT, Thom-sen RW. Incidence and outcomes of patients hospitalized with COPD exacerbation with and without pneumonia. Int J Chron Obstruct Pulmon Dis 2016; 11: 455‒65.
Vardeny O, Claggett B, Udell JA, Packer M, Zile M, Rouleau J, et al. Influenza Vaccination in Patients With Chronic Heart Failure: The Paradigm-HF Trial. JACC Heart Failure 2016; 4(2): 152–8.
Larson HJ, Cooper LZ, Eskola J, Katz SL, Ratzan S. Addressing the vaccine confidence gap. Lancet 2011; 378 (9790): 526–35.
Black S, Rappuoli R. A crisis of public confidence in vaccines. Sci Transl Med 2010; 2(61): 61mr1.
Zimmerman RK, Santibanez TA, Janosky JE, Fine MJ, Raymund M, Wilson SA, et al. What affects influenza vaccination rates among older patients? An analysis from inner-city, suburban, rural, and veterans affairs practices. Am J Med 2003; 114(1): 31–8.
Institute of Public Health of Srbija “Dr Milan Jovanovic Batut”. Re-sults of immunization conducted in Serbia 2016. Belgrade: In-stitute of Public Health of Serbia “Dr Milan Jovanović Ba-tut”; 2016. p. 1-8. [accessed 2017 Ocober 26]. Available from: http://www.batut.org.rs/ (Serbian)
Kopitovic I, Bokan A, Andrijevic I, Ilic M, Marinkovic S, Milicic D, et al. Frequency of COPD in health care workers who smoke. J Bras Pneumol 2017; 43(5): 351‒6. (English, Portuguese)